I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

@article{Sharief1999IvIR,
  title={I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barr{\'e} syndrome.},
  author={Moad K Sharief and Debbie Ingram and Michael Swash and Edward J. Thompson},
  journal={Neurology},
  year={1999},
  volume={52 9},
  pages={1833-8}
}
BACKGROUND Treatment with human i.v. immunoglobulin (IVIg) modifies the course of Guillain-Barré syndrome (GBS), but its specific mode of action is unknown. Cellular interactions mediated through the release of cytokines play a role in the pathogenesis of GBS and may be regulated by IVIg therapy. OBJECTIVE To delineate possible immunoregulatory mechanisms of IVIg in patients with GBS. METHODS Circulating levels of the proinflammatory cytokines, tumor necrosis factor (TNF)-alpha and… CONTINUE READING